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Abstract: Deregulation of the cholesterol pathway is an anomaly observed in human diseases, many
of which have in common neurological involvement and unknown pathogenesis. In this study
we have used Mevalonate Kinase Deficiency (MKD) as a disease-model in order to investigate the
link between the deregulation of the mevalonate pathway and the consequent neurodegeneration.
The blocking of the mevalonate pathway in a neuronal cell line (Daoy), using statins or mevalonate,
induced an increase in the expression of the inflammasome gene (NLRP3) and programmed cell
death related to mitochondrial dysfunction. The morphology of the mitochondria changed, clearly
showing the damage induced by oxidative stress and the decreased membrane potential associated
with the alterations of the mitochondrial function. The co-administration of geranylgeraniol (GGOH)
reduced the inflammatory marker and the damage of the mitochondria, maintaining its shape and
components. Our data allow us to speculate about the mechanism by which isoprenoids are able to
rescue the inflammatory marker in neuronal cells, independently from the block of the mevalonate
pathway, and about the fact that cell death is mitochondria-related.
Keywords: cholesterol pathway; apoptosis; neuroinflammation; mevalonate; mitochondria;
neuronal death
1. Introduction
The cholesterol pathway, commonly called the mevalonate pathway, is a crucial biochemical
process present in all higher eukaryotes and many bacteria [1,2]. It is a fundamental step for the
biosynthesis of several molecules involved in multiple processes as diverse as terpenoid synthesis,
protein prenylation, cell membrane maintenance, hormones synthesis, protein anchoring and
N-glycosylation [3,4] (Figure 1).
The inborn deregulation of the cholesterol pathway can lead to various pathological consequences.
Several of these diseases show a genetic mutation of various compounds along the mevalonate pathway,
such as coenzyme q10 deficiency (OMIM #612016; CoQ10) and mevalonate kinase deficiency (OMIM
#260920; MKD) [5,6].
Most of these diseases are rare and neglected, and are characterized by severe neurological
involvement that represents a convergent consequence of pathogenetic mechanisms linked to the
deregulation of the cholesterol pathway [7].
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Our group studied MKD in cellular and animal models—In which the genetic defect of human
MKD is mimicked by the biochemical blockade of the mevalonate pathway—Obtained using several
compounds able to affect the pathway at different levels, such as statins that block the mevalonate
pathway on enzyme HMG-CoA reductase [8] (Figure 1).
Figure 1. Schematic representation of the mevalonate pathway. The solid arrows represent the single
enzymatic reaction while the dashed arrows indicate multiple reaction steps.
In addition to their lipid-lowering effect, recent data have shown that statins play a neurotoxicity
role in cells by inhibiting proliferation, and inducing programmed cell death.
Structural differences of various statins (Atorvastatin, Fluvastatin, Lovastatin, Pitavastatin,
Pravastatin, Rosuvastatin, Simvastatin) support different pharmacokinetic responses, and this is
particularly evident in the diseases of the nervous system. It is thus essential to emphasize the
importance of identifying the precise mechanistic differences between statins in order to make the best
therapeutic decision, even though some molecular mechanisms induced by the statins have not yet
been fully understood [9].
To date it is commonly assumed that the biosynthesis of cholesterol in the central nervous system
occurs in situ, as a closed system, not dependent on systemic circulation [10–12].
The aim of our study is to understand the neurological effects of the cholesterol pathway blockade.
An MKD-neuronal model in vitro represents an effective tool to investigate the mechanism of activation
of inflammation linked to abnormalities in cholesterol traffic.
Recently we have demonstrated that the block of the cholesterol pathway on a neuronal cell line
induces caspase 3- and caspase 9-dependent programmed cell death [13–15].
To date, it is still unclear if the neuroinflammation induced by the block of the mevalonate
pathway depends on the accumulation of mevalonate or on the inhibition/block of the biochemical
process, and if both processes are associated to inflammation triggered by the mitochondria.
Several recent literature reports have drawn attention into the role of mevalonate-derived
isoprenoids, such as GGOH, in the regulation of several cellular processes and in the control of
inflammatory response to enzymatic regulation and response to oxidative stress [16,17]. Notably,
environmental factors can act in different ways in this scenario: nutritional factors can influence the
availability of substrates and the regulation of different enzymes in the mevalonate pathway; immune
stimuli such as infections and vaccinations can trigger an inflammatory response that involves several
prenylated proteins [18]; oxidative stress of various natures can exceed the antioxidant capacity of
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a defective mevalonate pathway, as described by Campia et al., that proved that GGOH co-treatment
with statins was able to rescue toxicity in THP-1 cells [19].
Finally, it can be interesting to understand if mechanisms of rescue, such as deployment of
isoprenoids, are able to restore the inflammatory mechanisms even in the case of accumulation of
mevalonate, as occurs when the pathogenic processes are induced by the block of the pathway [20].
To establish the comparable inflammatory effects on the different inhibition of the mevalonate
pathway due to the accumulation of the mevalonate or limiting the biosynthesis of compounds along
this biochemical process is fundamental to study the different levels of severity. The different approach
in the study of the pathogenesis of the mild and severe forms of MKD, should take into account
this molecular aspect: the reinforcement of the thesis according to which the MKD-inflammatory
phenotype is due to lack of isoprenoids, independently from the cause in the central nervous system,
would be crucial to identify an efficient pharmacological strategy.
For this reason, it is important to understand the role of the hypothetical accumulation of
mevalonate or of the lack of mevalonate-derived isoprenoids, in order to shed light on some steps of
the molecular pathogenesis of several diseases involved in the deregulation of the cholesterol pathway.
2. Results
2.1. Programmed Cell Death Triggered to Deregulation of the Mevalonate Pathway
The Apoptosis rate of Daoy treated with different compounds was analysed with Annexin
V-FITC Apoptosis Detection Kit. The treatment of cells with Simvastatin and Mevalonate showed
a statistically significant increase in the number of apoptotic cells, with a percentage of Annexin
V-positive cells respectively of 48.86% and 35.95%, compared to the 13.39% of the untreated cells
(** p < 0.01; *** p < 0.001) (Figure 2). Our results prove that Simvastatin is more effective and quick in
blocking the mevalonate pathway and inducing cell death in comparison to mevalonate.
Figure 2. Daoy cell line was incubated with Mevalonate (10 mM) and/or Simvastatin (10 µM) for 24 h
and with GGOH (50 µM) for an additional 24 h. Programmed Cell Death is expressed as percentage of
Annexin V positive cells (%A+) and bars represent the means % ˘ SD of five independent experiments.
Data analyses were performed with one-way ANOVA followed by Bonferroni post-test; * p < 0.05;
** p < 0.01, *** p < 0.001.
Treating cells with GGOH alone did not modify significantly the cell death rate (16.95%), while
administration in combination with Simvastatin or Mevalonate, restored the basal condition, nullifying
the alteration induced by Simvastatin and Mevalonate (from 48.86% to 21.17% for Simvastatin,
*** p < 0.001; from 35.95% to 19.13% for Mevalonate, * p < 0.05). The co-treatment of GGOH with Statin
and Mevalonate decreased partially the damage induced by this latest compounds and enhanced the
resistance of our neuronal cells to this disorder (Supplementary Figure S1).
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2.2. Mitochondrial Dysfunction Linked to Block of Cholesterol Production
To evaluate mitochondrial damage after the block of the mevalonate pathway in the Daoy cell
line, we assessed the impact of statins and mevalonate treatments on the mitochondrial membrane
potential (MMP), expressed as Median Fluorescence Intensity (MFI) of Rhodamine 123.
In Figure 3, Simvastatin and Mevalonate strongly down regulated the MMP, resulting in an MFI
of (427.7 ˘ 4) and (612.0 ˘ 40.4) respectively, compared to the control value (1153.0 ˘ 107.3).
Figure 3. The Daoy cell line was incubated with Mevalonate (10 mM) and/or Simvastatin (10 µM) for
24 h and with GGOH (50µM) for an additional 24 h. Bars represent the Mean Fluorescent Intensity
(MFI) of Rhodamine 123 ˘ SD of five independent experiments. Data analyses were performed with
one-way ANOVA and Bonferroni post-test; * p < 0.05; ** p < 0.01.
Treatment with GGOH alone (1020.0 ˘ 139.7) did not significantly change MMP in comparison
with the untreated condition, while in double treatment conditions GGOH upgraded the MMP in
Simvastatin (994.5 ˘ 158.1) and Mevalonate (1233.0 ˘ 160.1), restoring the control MFI level. These
results conclude that the statins and mevalonate in cells likely induce an alteration of ATP production
related to an increase of MMP causing mitochondrial damage.
2.3. Effect of the Block of the Mevalote Pathway on Cell Viability
The cytotoxic effect of Simvastatin on Daoy cells was confirmed with the xCELLigence system,
that analyses in real-time the viability of cultured cells, through electrical impedance monitoring.
The impedance graph (Figure 4) showed that Simvastatin (red line) induced a drastic decrease of the
CI, which is an indicator directly proportional to the area covered by cells. This reduction is restored
immediately after the administration of GGOH (pink line), added 24 h after the Simvastatin treatment.
The GGOH treatment alone (green line) is comparable to the untreated condition (blue line) and
does not perturb the growth curve of cells. In combination with the statin drug, however, it shows
a “positive” effect on cell viability.
Figure 4. Impedance profiles after Simvastatin treatment. Daoy were seeded (5 ˆ 105/well) in E-plate
and treated (at Time 0, after about 24 h seeding) with Simvastatin 10 µM and with GGOH 50 µM (after
about 48 h seeding). The graph shows the Normalized Cell Index, at the time of the first stimulation
(Time 0), indicated by the vertical black line. The experiment was performed in triplicate. Simva (red),
GGOH (green), Simva + GGOH (pink), Untreated (blue).
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The results obtained from the Mevalonate treatment alone or in the presence of the isoprenoid
are the same as those obtained by the statin, confirming the comparable kinetics of cell viability (data
not shown).
2.4. Inflammasome Platform Expression in the Presence of a Block of the Mevalonate Pathway
Inflammasome genes (NLRP1, NLRP3, CASP1 and ASC) expression in the Daoy cell line after
mevalonate and statin treatments, in presence or not of GGOH, was analysed and compared to
unstimulated cells (Figure 5).
Figure 5. NLRP3 gene expression levels of Daoy cells after different drug treatments were calculated
with respect to the untreated condition using the ∆∆Ct method. All data represent the results of three
independent experiments and are expressed as the mean of 2´∆∆Ct ˘ standard error (SE). β-Actin was
used for the normalization of all Ct values. Data analyses were performed with one-way ANOVA and
Bonferroni post-test; ** p < 0.01, *** p < 0.001 versus untreated.
NLRP3 expression was increased in Simvastatin (6.1 fold increase) and in Mevalonate treated-cells
(10.1 fold increase) when compared with the untreated condition (normalized to 1).
A significant decrease in NLRP3 mRNA expression was also measured after GGOH treatment on
Simvastatin (1.6 fold) and Mevalonate (3.8 fold) (** p < 0.01, *** p < 0.001).
This isoprenoid proved its influence in reducing the inflammation caused by the block of the
cholesterol traffic.
After 48 h of stimulation, neither the Simvastatin nor the Mevalonate treatments were able to
modify the expression of the other inflammasome genes, NLRP1, CASP1 and ASC (data not shown).
This results shows that among the inflammasomes, NLRP3 is the most involved in the defense of
the innate immune system in the Daoy cells.
2.5. Morphological Changes Correlated with Deregulation of the Mevalonate Pathway
The Daoy cell line exhibits normal sized and oval-shaped mitochondria, with tubular cristae, with
inner and outer membranes well defined (Figure 6A,G). The GGOH-treatment of the Daoy maintains
the regular shape of cells in which the mitochondria present tubular cristae and the membranes can
be observed in detail (Figure 6B,H). The biochemical block of the mevalonate pathway obtained with
Mevalonate (Figure 6E,M) causes an evident misshape of damaged and swollen mitochondria, and
several cristae are disrupted and leave large spaces in the inner area. Simvastatin-treatment leads to
a similar situation of a shrunken mitochondria showing condensed cristae coalesced in small groups
leaving empty spaces between them (Figure 6C,I).
The presence of GGOH in association with the block induced a significant change in morphology:
the Mevalonate+GGOH treatment, indeed, produced amelioration in mitochondria morphology.
They took a different shape with a thin and long form instead of the oval regular form (Figure 6F,N),
and cristae are recognizable. They have a regular structure and distribution and the double membrane
is better defined. The same results are observed in Simvastatin + GGOH cells treatment. GGOH
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co-treatment with Simvastatin or Mevalonate is able to reduce the injury of the mitochondria, enhancing
their form and components (Figure 6D,L).
Further images with an enlargement of mitochondria can be found in the Supplementary material,
to appreciate the different morphology after treatments (Supplementary Figure S2).
Figure 6. (1) Representative electron micrographs of Daoy cells incubated for 48 h in complete medium
with Simvastatin (10 µM) and Mevalonate (10 mM) in the presence or absence of GGOH (50 µM) for
24 h. For each picture, an enlargement of the image is displayed, showing the presence of normal or
damaged mitochondria (indicated by arrowheads). Scale bar, 1 µm; (2) Confocal microscopy of Daoy
cells after different treatments stained with Mito-ID (red fluorescence). Many fields were examined
and over 95% of the cells displayed the patterns of the respective representative cells shown here. Scale
bar, 20 µm. (A,G) untreated condition; (B,H): GGOH treatment; (C,I): Simvastatin treatment; (D,L)
Simvastatin + GGOH treatment; (E,M): Mevalonate treatment; (F,N): Mevalonate + GGOH treatment.
2.6. Supernatants Cytokines Levels in Daoy Cell Line Treated
The evaluation of cytokines production (IL-6 and TNF-α) was done 48 h after Simvastatin (10 µM)
or Mevalonate (10 mM) treatments considering that this was the experimental time required to obtain
the maximum increase in inflammatory markers. Simvastatin and Mevalonate induced a marked
increase in IL-6 levels (4072 ˘ 449 and 9094 ˘ 358 respectively) in comparison to the untreated
condition (2136 ˘ 105).
The anti-inflammatory response to GGOH treatment (3192 ˘ 258) was studied in Simvastatin
and Mevalonate conditions (2337 ˘ 157 and 3470 ˘ 213 respectively): the isoprenoid induced in both
conditions a marked decrease in IL-6 production (Figure 7).
Figure 7. Deregulated IL-6 production after treatments on Daoy cells: treatments with Simvastatin
(10 µM) and Mevalonate (10 mM) in the presence or absence of GGOH (50 µM) for 24 h. Geranylgeraniol
was dispensed 24 h after the Simvastatin or Mevalonate treatments. The concentration values of IL-6
(pg/mL) were obtained from experiments performed in triplicate. IL-6 was significantly modulated
with isoprenoids treatments. One way ANOVA test followed by the Bonferroni correction for multiple
comparisons * p < 0.05, ** p < 0.01, *** p < 0.001.
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The level of TNF-α was under the lower limit of detection (LLOD) in all evaluated conditions,
either because the level was very low or because this molecule is not produced by this neuronal
line [21,22].
3. Discussion
The cholesterol metabolic pathway is a biochemical process highly regulated and associated with
many life functions. The strong relationship between the regulation of this metabolic pathway and its
implications on the inflammatory process are much studied as they are involved in the pathogenesis
of many severe diseases, some of which are rare, and without a specific etiological treatment, as in the
case of MKD [4]. Mandey et al. investigated the inflammatory response associated with an alteration of
the mevalonate pathway in the MKD condition [16] in order to establish if the inflammatory response
was associated with an accumulation or lack of intermediate compounds of the biochemical process.
In our previous study, the results obtained from a monocytes cell line and from samples of MKD
patients, showed that the shortage of isoprenoid end products rather than an excess of mevalonate
is the cause of inflammatory events [23]. These data could justify the administration of exogenous
isoprenoids (i.e., GGOH) to compensate for the defective mechanism. Unfortunately, in the central
nervous system this may not occur, because of the closed mechanism with which the biosynthesis
and the consumption of cholesterol occur in situ. It is widely accepted that in the central nervous
system, most cholesterol is produced in glia cells. On the contrary, neurons are responsible for the
down-biosynthesis of cholesterol [24].
The role of microglia cells in the biosynthesis of neuroinflammation in MDK pathogenesis is very
interesting, but it is difficult to find cell lines of human microglia. A recent pilot study conducted by
our group with a co-culture of neuronal human cells and microglia mouse cells, showed that BV-2 is
a murine microglia cellular model useful to have a biomarker of cytokines production [25]. Recently,
however, a report showed that the knockdown of mevalonate kinase in BV-2 cells is not a suitable
MKD model, because NALP3 expression and cell death does not correspond to the expression obtained
from MKD patients [26].
Taking into account all these issues, it is crucial to establish if the neurons respond to the
deregulation of the mevalonate pathway as it happen for monocytes, and if the inflammatory response
is linked exclusively with the shortage of isoprenoids.
The block of the mevalonate pathway by Simvastatin or Mevalonate contribute both to the increase
of the inflammatory markers and to the activation of the NLRP3-inflammosome. Moreover, these
effects are associated with mitochondrial damage, as demonstrated by other authors in neurological
disorders, due to impaired cholesterol metabolism [27–30].
The significant cell death in Simvastatin or Mevalonate-treated Daoy cells in comparison with the
untreated condition shows that the block of the mevalonate pathway induces a dramatic morphological
change in mitochondria, independently from the inhibitor. The mitochondrial unit is essential for
energy production and redox homeostasis, responsible for cell life and death. Morphological changes
are accompanied by alterations in the mitochondrial function, which can be related to the production of
ROS (reactive oxidative species) and NO (nitric oxide), inducing a neuroinflammatory response leading
to programmed cell death, which in this experimental setting was further confirmed by mitochondrial
membrane potential.
Recent developments on the activation of NLRP3 and on damaged mitochondria, indicate that
ROS produced by the dysfunction of mitochondria have a crucial role in priming NLRP3, even though
the molecular mechanism underlying this process remains unclear [31,32].
Moreover, several cardiovascular disorders and metabolic syndromes, associated with cholesterol
pathway deregulation, have been related to mitochondrial damage characterized by an abnormal
balance of production between ROS and NO [33–35].
Int. J. Mol. Sci. 2016, 17, 365 8 of 12
The capacity of isoprenoids, such as GGOH, to reverse these inflammatory conditions appears
to be highly relevant. This capacity is supported by significant and evident changes in mitochondria
morphology [36].
The capacity of GGOH to restore the pathway and reduce the induced inflammation has been
highlighted through cytofluorimetric analysis and gene expression. Based on recently published
data we known that cell death associated to the block of the mevalonate pathway follows the
mitochondrial pathway, which is caspase-9 and caspase-3 dependent [14,15]. Observing these data,
we can hypothesise that isoprenoids (such as GGOH) are able to restore the physiological cellular
homeostasis, influencing the main actors of the mitochondrial damage (such as the components of the
Bcl-2 family members, Bax and Bak).
Moreover, IL-6, commonly considered as an inflammatory marker, can be adopted as an additional
indicator of the effect of GGOH: the isoprenoid is able to reduce the inflammatory marker in both
conditions by which we blocked the pathway. The evaluation of the TNF-α production has not led,
however, to significant results, and we believe the rationale behind this result should be searched in
the kinetics synthesis of the pro-inflammatory cytokines after a stimulus [37–39].
In conclusion, despite the important results obtained from this model, the mechanism by which
the blockage of the biochemical process induces neuroinflammation is poorly understood.
It would be easier to study this mechanism by working with neuronal cell lines from MKD
patients, but the main problem researchers are facing is represented by the difficulty of collecting
biological material and data. Indeed, the only information they can collect derives from the clinical
observation of patients showing psycho-motor disorders or from post-mortem analyses. For ethical
reasons, it is not possible to design experiments to directly study the neuronal tissue of patients, since
this type of analysis would also require samples collected from healthy age-matched controls.
The adoption of an MKD-neuronal biochemical model leads us to consider these results as
preliminary, but as a good starting point to better understand the link between the neurological
involvement and inflammatory aspects. The acquired knowledge on the neuronal apoptotic mechanism
could allow researchers to develop novel drugs for the still orphan MKD deficiency.
4. Materials and Methods
4.1. Reagents and Cell Culture
Geranylgeraniol (GGOH), Simvastatin (Simva, Mevinolin from Aspergillus terreus), and
Mevalonate (Mev) were obtained from Sigma Chemical Co. Aldrich (St. Louis, MO, USA) and
dissolved in saline solution (Simvastatin) or ethanol (Sigma Chemical Co. Aldrich, St. Louis, MO,
USA), which did not exceed 0.01% final concentration per well.
Daoy (human derived desmoplastic cerebellar medulloblastoma cell line), obtained from ATCC,
were cultured in EMEM (Eagle’s Minimum Essential Medium) (Euroclone, Italy), supplemented
with 10% foetal bovine serum (FBS, Euroclone, Italy), 2 mM glutamine and penicillin streptomycin
anphotericin B 1ˆ solution (Sigma Chemical Co. Aldrich, St. Louis, MO, USA).
Twenty-four hours after seeding in a 6 wells plate, 2 ˆ 105 cells were stimulated with Mev (10 mM)
or Simva (10 µM). After 24 h from the first treatment, Daoy were treated also with GGOH (50 µM).
Cells were incubated for further 24 h and were then harvested for the analysis.
4.2. Flow-Cytometry Analysis: Programmed Cell Death Assays and Mitochondrial Membrane Potential Assay
The programmed cell death of Daoy was analysed by flow cytometry using Annexin V (A)
and Propidium Iodide (PI) staining. Cells were stained with FITC-conjugated Annexin V and
Propidium Iodide (Annexin V-FITC Apoptosis Detection Kit, Immunostep, Spain) following the
customer indications. Briefly, 24 h after last stimulation, cells were harvested from the plate with a 0.5%
Trypsin-EDTA solution (Sigma Chemical Co. Aldrich St. Louis, MO, USA) and washed with PBS.
5 ˆ 105 cells were resuspended in the manufacturer’s Binding Buffer, stained with A and PI for 15 min,
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then acquired on flow cytometer. To evaluate the percentage of death cells, debris was excluded from
the plot based on the scatter, while the apoptotic and necrotic cells were characterized on the basis of
emitted fluorescence.
Changes in mitochondrial membrane potential (∆Ψm) were determined by Rhodamine
123 staining. In brief, after treatments, cells were harvested from the plate, washed in PBS and
suspended in 500 µL PBS. Cells were then stained with 10 µg/mL Rhodamine 123, at 37 ˝C for 30 min,
under agitation. Rhodamine 123 median fluorescence intensity (MFI) was measured by flow cytometry.
For all the experiments, data were acquired with CyAn ADP analyser and Summit software
(Beckman Coulter, CA, USA), then analysed with FlowJo software (version 7.6, Treestar, Inc. Ashland,
OR, USA).
4.3. The xCELLigence System and Analysis of Impedance
The effect of the pharmacological treatment (Simvastatin, Mevalonate and GGOH) was assessed
with the xCELLigence RTCA DP Instrument (Roche, Penzberg, Germany), that analyses the electrical
impedance due to cell adhesion on well bottom, covered by gold microelectrodes. With this automatic
system, the number, the morphology and the viability of attached cells are displayed as an alteration
of the impedance, that is recorded in real time as an adimensional parameter, called “Cell Index” (CI).
A decrease in CI, after adding a pharmacological compound, could be due to a detachment or to the
death of cultured cells. Briefly, for this analysis, 5 ˆ 103 Daoy were seeded in a 16 well plate (E-plate) in
200 µL of complete medium, and cultured in 5% CO2 at 37 ˝C. The cells were stimulated following the
same experimental design described in Section 4.1. The impedance was measured every 15 min before
the pharmacological treatment and every 2 min after drug administration. This assay was repeated
twice in triplicate.
4.4. RNA Isolation and Real Time-PCR
Total RNA was isolated using the RNAqueous-Micro kit (Ambion, Thermo Fisher Scientific,
Waltham, MA, USA). First-strand complementary cDNA was synthesized from 1 µg of extracted
RNA in a 20 µL reaction volume using High Capacity cDNA Reverse Transcription Kits (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s protocol.
NLRP1, NLRP3, CASP1 and PYCARD were amplified with specific TaqMan® Gene Expression
Assays (Hs00248187_m1, Hs00366465_m1, Hs00354836_m1, hs00203118_m1) with TaqMan Gene
Expression Master Mix (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) using the
7500 Fast DX Real Time PCR Instrument (Applied Biosystem, Thermo Fisher Scientific, Waltham, MA,
USA). The housekeeping gene ACTB (Hs99999903_m1) was used for normalization. Raw fluorescent
data of Ct values were corrected based on PCR efficiencies using LinRegPCR [40]. The relative
quantitative expression of the selected transcript was calculated using the ∆∆CT methods [41].
Experiments were performed in triplicates and analysis of each experiment was executed in duplicate
wells, in the same experimental setup described in Section 4.1.
4.5. Immunohistochemistry
Pellets were fixed with 2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in
0.1 cacodylate buffer, pH 7.3, for 1 h at room temperature, rinsed twice for 10 min in 0.1 cacodylate
buffer and postfixed with 1% osmium tetroxide in the same buffer for 1 h at 4 ˝C (Hayat, Basic
techniques for transmission electron microscopy, Academic Press, Inc., Orlando, FL, USA, 1986).
Pellets were dehydrated in ascending alcohols, treated with propylene oxide and embedded in Araldite
(Electron Microscopy Sciences, Hatfield, PA, USA). Ultrathin sections of the samples were cut on a Top
Ultra 150 ultramicrotome (Pabish, Germany) and collected on 300-mesh copper grids. The grids were
stained with uranyl acetate and lead citrate and examined at 80 kV using a Jeol JEM 100S transmission
electron microscopy.
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4.6. Confocal Microscopy
Daoy cell line was primed with GGOH on coverslips (4 ˆ 105 cells per coverslip), placed in
a 12 well plate and treated for 24 h with Mevalonate or Simvastatin. Cells adhered on coverslips,
were then washed with PBS and the intracellular localization of fullerenes was traced using the
mitochondrial marker MitoTracker Red (CMXRos) (Molecular Probes, Eugene, OR, USA) for 15 min
at 37 ˝C following the instructions of the manufacturer. Cells were examined using a Nikon C1-SI
confocal microscope (TE-2000U) equipped with a 60ˆ oil immersion lens.
MitoTracker Red was visualized using the 561 nm length diode laser for excitation and
a 590 dichroic mirror with a 50 nm band emission filter was used to record emission. All images were
acquired in the linear intensity window and with no visible saturation points. The pixel resolution was
100 nm for X and Y axis and z-step was established at 300 nm. Representative images are z-projection
performed using standard deviation algorithm in ImageJ software (NIH).
4.7. Determination of Cytokines Release
The analyses of cytokines (including: interleukin 6 (IL-6), and tumour necrosis factor α (TNF-α),
were performed on supernatant samples using a magnetic bead-based multiplex immunoassays
(Bio-Plex®) (BIO-RAD Laboratories, Milano, Italy) following manufacturer’s instructions. Data from
the reactions were acquired using the Bio-Plex® 200 reader, while a digital processor managed data
output and the Bio-Plex Manager® software returned data as Median Fluorescence Intensity (MFI) and
concentration (pg/mL).
4.8. Data Analysis
All results are expressed as the mean ˘ standard deviation (SD). Statistical significance was
calculated using a one-way analysis of variance (ANOVA) and Bonferroni post-test correction in the
case of multiple comparisons. Analysis was performed using GraphPad Prism software (version 5.0).
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/
3/365/s1.
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